Skip to main content
Premium Trial:

Request an Annual Quote

Naveed Shams

Opko Health said this week that it has appointed Naveed Shams as its chief medical officer and senior vice president of research and development.
Before joining Opko, Shams worked at Genentech where he oversaw development of that company’s wet age-related macular degeneration drug Lucentis. Opko is developing its own AMD treatment, an RNAi drug called bevasiranib, which is under phase III development (see RNAi News, 9/6/2007).


Shams holds an MD from Dow Medical College in Pakistan and a PhD in microbiology and immunology from the University of South Carolina.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.